



Denver

CHEMISTRY

Spring 2023

Seminar Series



11am-12pm

March 17th

NC 1130

in-person

Prof. Daniel V. LaBarbera

Director of the Center for Drug Discovery

Department of Pharmaceutical Sciences, Skaggs School of
Pharmacy and Pharmaceutical Science, CU Anschutz
Medical Campus

"Drug discovery and development of the first-in-class lead drugs targeting oncogenic CHD1L for the treatment of cancer"

Chromodomain Helicase DNA Binding Protein 1 Like (CHD1L), also known as Amplified in Liver Cancer 1 (ALC1), is a chromatin remodeling enzyme and contemporary oncogene implicated in tumor progression, metastasis, and multidrug resistance in many types of cancer. This presentation will discuss the high-throughput (HTS and HCS) drug discovery, lead validation, medicinal chemistry optimization, and in vitro and in vivo pharmacology of the first- and best-in-class inhibitors and lead drugs targeting CHD1L in cancer.

Key Words: Cancer, Oncogene, CHD1L, ALC1, HTS/HCS discovery, lead drug optimization

For more information see: <https://clas.ucdenver.edu/chemistry/seminars-and-events>